Steeper Periovulatory Estradiol Decline Associated With Lower Clinical Pregnancy Rates in Fresh GnRH Antagonist ICSI Cycles

Estradiol drops after the hCG trigger and the study found that the steeper the fall, the lower the clinical pregnancy rate.

In a single-center retrospective cohort of 849 fresh GnRH-antagonist ICSI cycles, researchers split patients by the proportional change in serum estradiol from trigger day to retrieval day. The group with the steepest decline — 45 % or more — saw a clinical pregnancy rate of 30.5 %.

The middle group, with a 30 % to 45 % drop, reached 45.5 %, while cycles where estradiol fell 30 % or less, or even rose, hit 43.6 %. The difference held after multivariable adjustment, yielding an adjusted odds ratio of 1.090 per 10-percentage-point increase in estradiol change (95 % CI 1.005–1.183; p = 0.038). Generalized estimating equations accounting for repeated cycles confirmed the association.

The periovulatory window under scrutiny

The study enrolled 727 patients undergoing fresh ICSI cycles. Clinicians used a standard antagonist protocol with hCG trigger; blood draws on trigger day and retrieval day provided the estradiol delta. Fertilization rates, top-quality embryo availability, and the number of embryos transferred were comparable across the three groups, yet pregnancy rates diverged. Spontaneous abortion rates did not differ.

“A more pronounced periovulatory estradiol decline remained modestly associated with lower odds of clinical pregnancy despite similar top-quality embryo availability,” the authors wrote. They suggest the proportional change may serve as a complementary marker of the periovulatory hormonal transition, adding a data point to the longstanding debate over optimal trigger timing and luteal-phase support.

Context from earlier work

A 2016 Medicine paper by Hu and colleagues examined criteria for hCG trigger timing in antagonist cycles. The 2014 Cochrane review by Youssef et al. compared GnRH-agonist versus hCG triggering, while a 2022 BMC Pregnancy and Childbirth study by Dong et al. evaluated dual trigger versus hCG alone.

Most recently, a 2026 paper in the Journal of Assisted Reproduction and Genetics by Chen et al. reported that the magnitude of post-retrieval estradiol decline directly compromises clinical pregnancy and live birth rates in high responders.

Whether adjusting luteal estradiol supplementation based on this proportional change improves outcomes remains untested in a prospective trial. A 2024 randomized controlled trial by Li et al. in Reproductive Biology and Endocrinology showed benefit from estradiol supplementation after a substantial post-trigger drop, but that study used absolute thresholds rather than the proportional metric highlighted here.